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BACKGROUND: Prostate cancer (PrCa) is one of the most common cancers affecting men but its aetiology is poorly understood.
Family history of PrCa, particularly at a young age, is a strong risk factor. There have been previous reports of increased PrCa risk in
male BRCA1 mutation carriers in female breast cancer families, but there is a controversy as to whether this risk is substantiated. We
sought to evaluate the role of germline BRCA1 mutations in PrCa predisposition by performing a candidate gene study in a large UK
population sample set.
METHODS: We screened 913 cases aged 36–86 years for germline BRCA1 mutation, with the study enriched for cases with an early age
of onset. We analysed the entire coding region of the BRCA1 gene using Sanger sequencing. Multiplex ligation-dependent probe
amplification was also used to assess the frequency of large rearrangements in 460 cases.
RESULTS: We identified 4 deleterious mutations and 45 unclassified variants (UV). The frequency of deleterious BRCA1 mutation in this
study is 0.45%; three of the mutation carriers were affected at age p65 years and one developed PrCa at 69 years. Using previously
estimated population carrier frequencies, deleterious BRCA1 mutations confer a relative risk of PrCa of B3.75-fold, (95% confidence
interval 1.02–9.6) translating to a 8.6% cumulative risk by age 65.
CONCLUSION This study shows evidence for an increased risk of PrCa in men who harbour germline mutations in BRCA1. This could
have a significant impact on possible screening strategies and targeted treatments.
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Prostate cancer (PrCa) is one of the most common cancers
affecting men worldwide; in the United Kingdom, PrCa incidence
has overtaken lung cancer with 37000 cases and 10000 deaths
reported in the latest statistics since 2008. Worldwide there were
4900000 cases diagnosed and B250000 deaths reported in 2008
(CRUK CancerStats August 2011). However, the underlying
aetiology is complex and poorly understood compared with other
common complex diseases. The only well-established risk factors
are age (60% of men diagnosed with PrCa are 470 years old),
family history (first-degree relatives have an B2-fold risk
compared with the general population) and ethnic background
(men of African descent have an increased risk of PrCa). Recently,
common genetic variants (minor allele frequency 45%) that
individually account for a moderate increase in PrCa risk (relative
risk (RR) o2) were identified by the initial PrCa genome-wide
association studies (GWAS; Eeles et al, 2008; Gudmundsson et al,
2008; Thomas et al, 2008), these and subsequent follow-up studies
have now found 440 PrCa risk alleles (reviewed in Goh et al,
2012). Predisposition genes with a higher RR have proven more
difficult to identify.
Studies on twins were instrumental in providing evidence for the
existence of a substantial genetic component in PrCa risk, with
identical twins being B5 times more likely to be concordant with
PrCa compared with non-identical twins (Gro ¨nberg et al, 1994;
Page et al, 1997). A large Scandinavian twin study into the causes
of cancer reported that genetic factors accounted for 42% of the
PrCa risk in their sample set and concluded that both rare highly
penetrant variants and common polymorphisms with low pene-
trance contribute to PrCa risk (Lichtenstein et al, 2000).
Deleterious germline mutations in BRCA1 and BRCA2 increase
the risk of breast and ovarian cancer in women, and co-
aggregation of PrCa and breast cancer was initially established in
epidemiological studies of breast cancer families (Thompson and
Easton, 2001, 2002). For BRCA1 mutation carriers the Breast
Cancer Linkage Consortium reported an increase in PrCa risk in
men aged o65 years with a RR of 1.82 (95% confidence interval
(CI) 1.01–3.29, P¼0.05), but no risk increase was seen for men
X65 years. For BRCA2 mutation carriers the study reported an
increase in PrCa RR of 4.65 (95% CI 3.48–6.22) rising to 7.33 (95%
CI 4.66–11.52) for men o65 years (The Breast Cancer Linkage
Consortium, 1999). The frequency and risk estimates for BRCA2
mutation carriers was addressed by several studies, most
comprehensively it was recently evaluated in a large cohort by
our group (Kote-Jarai et al, 2011), which reported an B8.6-fold
increased risk of PrCa for BRCA2 mutation carriers.
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sHowever, most BRCA1 mutations reported in PrCa cases to date
were identified through familial breast/ovarian cancer studies and
PrCa-specific studies restricted to specific populations and
assessment of founder mutations (Kirchhoff et al, 2004; Cybulski
et al, 2008). Therefore, these studies are likely to be underpowered
to assess accurately a BRCA1 mutation carrier’s risk of PrCa. Here,
we report the first large-scale (913 cases) prostate centric study,
using direct Sanger sequencing and multiplex ligation-dependent
probe amplification (MLPA) to provide a comprehensive assess-
ment of germline BRCA1 genetic variation across the entire coding
sequence and proximal promoter region of this gene in PrCa cases.
MATERIALS AND METHODS
Samples
A series of men with PrCa were recruited from the UK Genetic
Prostate Cancer Study (UKGPCS) as reported previously
(Eeles et al, 1997). The majority (546, 83.4%) of patients with a
known diagnosis method (655/913) had clinically presenting (not
prostate-specific antigen (PSA) screened) disease. Case selection
for this study was based primarily on age at diagnosis of p65 years
(821 cases; age range 36–65 years); with a further cohort aged 465
years (92 cases; age range 66–88 years) with a family history of one
or more first-degree relatives with PrCa (Table 1).
Mutation detection
Germline DNA was obtained from peripheral blood samples and
extracted as reported previously (Edwards et al, 1997). A total of 29
primer pairs were designed using primer3 and exonprimer (Rozen
and Skaletsky, 2000; http://ihg.gsf.de/ihg/ExonPrimer.html) to
cover all exons, intron/exon junctions, proximal promoter and
exon 1a/b region of the full-length NM_007294.3 mRNA transcript;
primer sequences available on request. Using Qiagen multiplex
PCR kit 206145 (Qiagen, Hilden, Germany), the 29 primer pairs
were grouped into four multiplexs (3 7 multiplexes and 1 6
multiplex) and two singleton reactions. The amplicons were
sequenced on an ABI3730 Genetic Analyzer using a 1/16th BigDye
v3 protocol (Applied Biosystems, Foster City, CA, USA). Deleter-
ious mutations were confirmed by Sanger sequencing using a
different aliquot from stock DNA of each sample. Multiplex
ligation-dependent probe amplification was performed on a subset
of 460 samples using a modified protocol of the SALSA MLPA kit
P002-C2 (MRC-Holland, Amsterdam, The Netherlands).
Sequence analysis
Mutation surveyor 3.97 (Softgenetics, State College, PA, USA) was
used to analyse the sequencing data, using a region of interest
covering 500bp of the near promoter exons 1–3, 5–24 and also
including ±20bp per exon to screen the intron/exon boundaries.
Results were exported to Human Genome Variation Society
nomenclature and converted to hg19 genomic coordinates using
Mutalyzer 2.0 b-8, (http://www.mutalyzer.nl/) to allow variant
annotation using ANNOVAR (Wildeman et al, 2008; Wang et al,
2010). Variants were designated as ‘novel’ if they were not
described in dbSNP132, Breast cancer Information Core (BIC) or
the Leiden Open Variation Database as of July 2011 (Szabo et al,
2000; Sherry et al, 2001; Fokkema et al, 2011).
Statistical methods
Estimates for BRCA1 prevalence in the general population were
derived from a study where a large population series and a set of
high-risk breast cancer families from the United Kingdom were
analysed incorporating the effect of BRCA1, BRAC2 and other
genes to account for residual family history (Antoniou et al, 2002).
Confidence intervals for the prevalence of BRCA1 mutations
among PrCa cases and hence the CIs on RR were computed using
an exact binomial procedure. Age-specific cumulative risks of PrCa
to age 65 in BRCA1 mutation carriers were computed based on the
RR estimated from this study and age-specific pooled incidence
rates from five cancer registries in England for the year 2002 as
reported in Ferlay et al (2007).
RESULTS
We screened 913 PrCa cases for germline mutations in the BRCA1
gene using direct Sanger sequencing. After quality control (QC)
exclusions, data from 886 PrCa cases were analysed. We identified
four deleterious mutations (0.45%), of which three were frame-
shifts and one was a splice site mutation (Table 2). A subset of the
PrCa cases (460) was also screened for large-scale rearrangements
(LGRs) using MLPA, none were found in our sample set.
All four deleterious mutations had been previously recorded in
BIC (http://research.nhgri.nih.gov/bic/). We also identified
45 missense variants (10 novel), 15 synonymous substitutions
(5 novel) and 6 intronic variants (1 novel; Supplementary Table 1).
The majority of deleterious mutations occurred in PrCa cases o65
years (3 out of 4) and all mutations are within two distinct
functional domains of BRCA1; mutations c.68_69delAG (A) and
c.212þ1G4T (B) in the N-terminus RING finger domain
and c.1954dupA (C) and c.2475delC (D) in the large central
DNA-binding domain (Figure 1).
In addition we have also identified several missense unclassified
variants (UV) and a deletion in the proximal promoter region,
c.1-1462delC immediately 30 of a CREB-binding site regulated
by methylation (Mancini et al, 1998; Atlas et al, 2001; DiNardo
et al, 2001).
The missense UVs identified were annotated by ANNOVAR
against dbNSFP normalised (0–1) scores for SIFT, Polyphen2, LRT,
MutationTaster and Phylop, (Chun and Fay, 2009; Kumar et al,
2009; Adzhubei et al, 2010; Pollard et al, 2010; Schwarz et al,
2010; Liu et al, 2011). In addition, all non-synonymous SNPs
were annotated with Align-GVGD (Mathe et al, 2006; Tavtigian
et al, 2008). The intersection of UVs predicted to be ‘probably
damaging’ by both SIFT and Polyphen2 selects 13 of the 45 UVs
found in the study, of which 11 are in BIC and 2 are novel
(Supplementary Table 1). Of the BIC annotated mutations three
are classed as ‘of no clinical significance’, the rest as ‘of unknown
significance’, whereas 10 of these 13 variants have been classified
as ‘of no clinical significance’ using multifactorial likelihood
approaches (Valle ´e et al, 2011). This leaves three variants, H279Q,
M1400R and M1783T (Supplementary Table 2) with some potential
to be deleterious, although only M1783T is situated in a known
functional domain (BRCT repeat 2).
Based on the previously estimated carrier frequency of BRCA1
mutations in the United Kingdom (which estimated the allele
Table 1 Age range and family history of PrCa samples screened for
BRCA1 germline mutation
Age
range
(years)
Number
of
samples
% PrCa
family
history
a
% Br/Ov
family
history
a
%
Samples
deceased
Number
of
carriers
%
Carriers
36–55 327 37.3 26.0 13.1 1 0.3
56–65 494 53.0 28.7 12.8 2 0.4
66–88 92 100.0 31.5 22.8 1 1
Total 913 4
Abbreviations: BrCa¼breast cancer; OvCa ¼ ovarian cancer; PrCa ¼ prostate
cancer. Family history of (BrCa) and (OvCa) is also shown.
aIn first- and
second-degree relatives.
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sfrequency of BRCA1 mutation to be 0.006 corresponding to a
carrier frequency of 0.0012 (B1/1000), Antoniou et al, 2002) and
the observed prevalence of BRCA1 mutations in our series of
PrCa cases of 4/886 (0.45%), we estimate that germline mutations
in the BRCA1 gene confer a RR of PrCa of B3.75-fold, (95% CI
1.02–9.6).
DISCUSSION
This study utilised direct Sanger sequencing to screen the complete
BRCA1 coding transcript (NM_007294.3) in 913 PrCa patients, the
majority of whom were clinically detected (83.4% of cases for
which the diagnosis method was reported). This is the largest
direct sequencing study of BRCA1 reported so far in PrCa and
therefore presents the most comprehensive assessment of the
contribution of BRCA1 mutations to PrCa risk.
After QC, 886 PrCa cases were included in our mutation analysis
of the sequencing data and four pathogenic mutations were
identified (0.45%). In the 460 samples, which were also submitted
for MLPA, no LGRs were identified.
Of the four identified pathogenic mutations, c.68_69delAG (BIC
185delAG) is a well-known Ashkenazi-Jewish founder mutation
(reported 1979 times in BIC), which has been extensively studied
and has a frequency of B1% in the general Ashkenazi-Jewish
population. From the UK 2001 census, 266740 people (0.5% UK
population) are recorded Jewish as their religion; however, this is
believed to be an underestimate due to the non-counting of secular
Ashkenazi-Jews and the self-reporting nature of this statistic.
A recent meta-analysis on six Ashekenazi-Jewish studies of PrCa
(3005 cases and 6834 controls) by Fachal et al showed a non-
statistically significant odds ratio 1.8 (95% CI 0.91–3.57; P¼0.09)
for this particular mutation (Fachal et al, 2011). This correlates
with the observation by Al-Mulla et al, 2009, where breast cancer
patients with BRCA1-truncating mutations in exon 2 (28/30
mutations assessed were c.68_69delAG) had a significantly higher
age of diagnosis compared with carriers of mutations in exons 11,
13 and 20, therefore suggesting protein-truncating mutations in
exon 2 have a lower penetrance than would be expected in this
gene. The c.68_69delAG mutation has also been found in the non-
Ashkenazi-Jewish, Spanish and UK (Yorkshire) populations, with
haplotype evidence for this mutation having arisen by independent
mutational events in different populations (Neuhausen et al, 1996;
Fackenthal and Olopade, 2007). Therefore, without detailed
haplotype analysis it cannot be determined which ancestry is
relevant in this study. The carrier of this mutation in our study was
diagnosed with PrCa at 58 years and following treatment had
12 years disease-free survival.
The c.212þ1G4T (BIC IVS5þ1G4T) mutation disrupts the
splice donor site, allowing read-through into the intron and
termination of transcription at codon 64. This mutation has also
been observed in a Spanish breast cancer study in a family with
breast and bladder cancers (Diez et al, 2010). The patient with this
mutation was diagnosed at 57 years and survived for only 3 years
after diagnosis; he also has a close relative who was diagnosed with
bladder cancer.
The c.1954dupA (BIC 2080insA) mutation is a frame-shift
causing insertion, resulting in termination of transcription at
codon 672 and has been reported as a Pakistani founder mutation
(Liede et al, 2002).
The c.2475delC mutation (BIC 2594delC) is a frame-shift
deletion, resulting in termination at codon 845. This mutation
appears to be a Scandinavian/Northern European founder muta-
tion from the ethnicity of the study samples recorded in BIC and in
two Scandinavian studies (Johannsson et al, 1996; Thomassen
et al, 2008).
The incidence of truncating BRCA1 mutations in this study for
PrCa cases diagnosed at p65 years (3/802) is 0.37%, and 0.45% in
all cases (4/886). Of the four pathogenic mutations identified, only
one patient had a family history of PrCa (father, age unavailable),
one patient had a family history of bladder cancer (brother, age
unavailable) and two patients were from families with first-degree
relatives with breast or ovarian cancer (details in Table 2). The
small number of mutation carriers does not allow the statistical
evaluation of the tumour characteristics in this study; however,
we have conducted a clinical assessment of a much larger set
of BRCA1 and BRCA2 mutation carriers and non-carrier PrCa
cases, which indicates that both BRCA1 and BRCA2 mutations
confer a more aggressive PrCa phenotype (Castro et al,
submitted).
Based on the previously estimated carrier frequency of BRCA1
mutations in the United Kingdom, we estimate that germline
mutations in the BRCA1 gene confer a RR of PrCa of B3.7-fold
and this translates to an 8.6% cumulative risk by the age of 65
years. Other studies have estimated higher frequencies of BRCA1
mutation prevalence but these did not allow for the presence of
other genetic effects (Whittemore et al, 2004). It is important to
emphasise that in addition to the population frequency of BRCA1
mutations various other factors could influence the estimates of
RR. Also, if one or more of the missense changes (UVs) were
pathogenic, the risk estimates would be higher. On balance our
estimate of B3.7-fold increased risk for BRCA1 mutation carriers
is accurate based on incidence rates in the United Kingdom.
Several studies addressed the estimation of PrCa risk by modelling
and incorporating various factors such as PSA level (Thompson
et al, 2006) or the recently discovered common genetic variants
found by GWAS (Macinnis et al, 2011). This latest model also has
Table 2 Patient information for protein-truncating mutation carriers
Sample
ID
Nucleotide
change
Age at
diagnosis
(years)
Tumour
stage
Node
stage Metastases
Final
gleason
Years to
death
FH of
prostate
cancer FH of Br or Ov
FH of other
cancers in family
PR-1 c.68_69delAG 58 T1a N0 M0 3þ3 12 (Alive) No Mother Ov No
PR-2 c.212þ1G4T5 7 T 4 N xM x4 þ4 3 No Sister Ov, aunt Br,
grandmother Br
Mother bladder,
grandfather colon
PR-3 c.1954dupA 51 Tx Nx M0 — 11 No No Brother Bladder
PR-4 c.2475delC 69 Tx Nx Mx — 8 Father No No
Abbreviations: Br¼breast cancer; Ov¼ovarian cancer. Clinical and family history (FH) data are detailed here if available. Tx, Nx and Mx if status unknown.
NLS A B C D BRCT domains
8–96 200–300
R
i
n
g
DNA binding SCD
452–1079 1280–1524 1646–1859
Figure 1 Schematic diagram of the positions of the deleterious
mutations (A–D) found in this study within the BRCA1 transcript. The
locations of the functional domains are marked in blue or green.
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sthe capacity to incorporate clinical information and effect of
rare genes once this becomes available.
These results suggest that routine testing of early onset PrCa
cases for germline BRCA1 mutations would further help to refine
the prevalence and risk associated with BRCA1 mutations and may
be useful for guiding management options.
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